Postpartum Hemorrhage Clinical Trial
Official title:
Comparison Between Celox Versus Bakri Balloon for Treatment of Primary Atonic Postpartum Hemorrhage
Postpartum hemorrhage (PPH) is responsible for around 25% of maternal mortality worldwide
reaching as high as 60% in some countries.
Postpartum hemorrhage is defined as loss of 500 mL or more in a vaginal delivery and 1 Litre
or more in a cesarean delivery.Also any blood loss that cause hemodynamic instability should
be considered a PPH.
In 2012, WHO updated the guidelines for the management of PPH and retained placenta to
include: "The use of intrauterine balloon tamponade is recommended for the treatment of PPH
due to uterine atony. This recommendation is now stronger than the previous guidelines. It
can be used for women who do not respond to uterotonics or if uterotonics are not available.
This procedure potentially can avoid surgery and is appropriate while awaiting transfer to a
higher-level facility".Furthermore, FIGO included Uterine balloon tamponade as a recommended
second-line intervention for the treatment of PPH in their updated guidelines issued in 2012.
In 2006, the ACOG Practice Bulletin, published by the American College of Obstetricians and
Gynecologists, made mention of the Bakri postpartum balloon for its specifically tailored
design that enables conservative management of uterine bleeding in cases of uterine atony and
other causes of PPH.
The reports demonstrated that balloon tamponade is helpful in managing PPH secondary to a
wide variety of causes in resource-poor settings.
One of the new methods that could be used to control PPH is Uterine packing with
chitosan-covered gauze or Celox.
Celox Haemostats are dressings with natural material called chitosan to control major
haemorrhage including life-threatening bleeding . They are simple and effective, stopping
major bleeding.It was first used by military forces to stop sever bleeding in the scene with
no other options to stop bleeding. Celox™ granules are actually very high surface area
flakes. When they come in contact with blood, Celox™ swells, gels, and sticks together to
make a gel like clot, without generating any heat. Celox™ does not set off the normal
clotting cascade, it only clots the blood it comes directly into contact with. Celox works on
casualties using anticoagulants and anti-platelet therapy such as aspirin .
Balloon tamponade is helpful in managing PPH secondary to a wide variety of causes in
resource-poor settings.
One of the new methods that could be used to control PPH is Uterine packing with
chitosan-covered gauze or Celox.
Celox Haemostats are dressings with natural material called chitosan to control major
haemorrhage including life-threatening bleeding . They are simple and effective, stopping
major bleeding.It was first used by military forces to stop sever bleeding in the scene with
no other options to stop bleeding. Celox™ granules are actually very high surface area
flakes. When they come in contact with blood, Celox™ swells, gels, and sticks together to
make a gel like clot, without generating any heat. Celox™ does not set off the normal
clotting cascade, it only clots the blood it comes directly into contact with. Celox works on
casualties using anticoagulants and anti-platelet therapy such as aspirin.
We will be having two groups:
1. Celox group:
Celox placement is very simpe . During cesarean section celox is loaded in the lower
uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs
after vaginal delivery the celox is inserted through the cervix to pack the lower
uterine segment. Removal of Celox after 24 hours.
2. Bakri balloon group:
Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter.
Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under
ultrasound guidance; making sure that the entire portion of the balloon passes the cervical
canal above the internal cervical os. Once the correct placement is confirmed, inflate the
balloon with sterile saline using the enclosed syringe.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 | |
Completed |
NCT03344302 -
Oxytocin Administration During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 |